JAK2 and melanoma: Numerous studies have revealed the molecular mechanisms underlying lack of T-cell infiltration and resistance of melanomas to immune checkpoint therapy, such as the melanoma-intrinsic active WNT/β-catenin-signaling pathway (23) and enrichment for mutations in PTEN (24), loss-of-function mutations in Janus kinase (JAK1)/JAK2 (which are involved in IFNγ signaling), and β2 microglobulin (an MHC class I subunit) (25, 26).